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Summary Drug resistance in haemopoietic cells may be partly related to the expression of the glutathione-s-
transferase (GST) pi and mdr-l genes. We have used RNA slot blotting techniques to investigate the
expression of GST pi in peripheral blood and bone marrow of eleven normal subjects, nine patients with
myelodysplastic syndrome (MDS), eighteen patients with acute myeloblastic leukaemia (AML), and thirty-two
patients with chronic lymphocyte leukaemia (CLL). We found increased expression of GST pi in 8 of 9 MDS,
(7 peripheral blood, I bone marrow) 12 of 18 AML (5 peripheral blood, 7 bone marrow; 4 of 5 untreated, I of
5 secondary, 7 of 11 relapse or refractory) and in the peripheral blood of 24 of 32 CLL (3 of 7 untreated, 21 of
25 treated) relative to normal controls. Increased expression of GST pi can occur at any stage of disease and
shows no clear relation to mdr-l expression except, possibly, in CLL. In 3 AML patients GST pi transcript
levels were the same or lower on relapse compared to presentation. Upregulation of the GST pi gene could not
be demonstrated in 2 CLL patients in response to treatment with intermittent chlorambucil.
Resistance to cytotoxic drugs, either at presentation, or,
more frequently, at relapse, is commonly encountered during
the treatment of leukaemia. It is well established in vitro that
cellular acquisition of the multidrug resistant (MDR)
phenotype confers loss of sensitivity to a wide range of
structurally unrelated toxins (Biedler & Riehm, 1970; Kartner
et al., 1985). Several distinct drug resistance processes are
now recognised which may be involved in clinically resistant
leukaemia (Holmes, 1990b). The mdr-I gene encodes the
transmembranous P-glycoprotein (PGP, Mr = 170,000) which
acts as an energy-dependent efflux pump and is associated
with decreased intracellular accumulation of drugs (Chen et
al., 1986; Juliano & Ling, 1976). The function of the protein
encoded by the mdr 2 gene in man is unknown. Mdr-1 gene
amplification and increased expression have been seen in the
drug-resistant CEM/VLB/100 leukaemia cell line when com-
pared to the parental sensitive CCRF-CEM line. However,
mdr 1 gene amplification has not been observed in AML or
MDS (Holmes et al., 1989). Elevated mdr 1 mRNA levels
have been reported in many forms of leukaemia (Goldstein et
al., 1989; Holmes et al., 1989, 1990a).
The glutathione-s-transferases (GST) have also been imp-
licated in drug resistance (Hayes & Wolf, 1988). They comp-
rise four gene families which map to distinct chromosomal
locations. Three of these gene families encode cytosolic pro-
teins which have been classified as alpha, mu, and pi (Man-
nervik et al., 1985). GST isozymes catalyse the conjugation
of electrophilic drugs, toxins and carcinogens to reduced
glutathione which leads to detoxification. They also detoxify
organic hydroperoxides and bind and sequester other foreign
compounds (Ketterer et al., 1986). Increased expression of a
variety of GST subunits has been observed in cell lines made
resistant to cytoxic drugs. (Hayes & Wolf 1988). In certain
cases concomitant over expression of both GST pi and mdr-1
mRNA have been observed (Cowan et al., 1986). Over ex-
pression of both mdr-l and GST has also been seen in
carcinogen-induced preneoplastic lesions in rat liver
indicating that there may be co-ordinate expression of these
proteins (Kitahara et al., 1984). Elevated levels of GST pi,
mRNA have been found in a variety of haematological
malignancies but no clear relationship with chemotherapy
can be determined. (McQuaid et al., 1989; Moscow et al.,
1989).
The myelodysplastic syndrome (MDS) represents a group
of conditions characterised by peripheral cytopenias and
ineffective haemopoiesis. Many patients go on to develop
acute myeloblastic leukaemia (AML). In addition, AML can
arise de novo, or secondary to chemotherapy for malignancy,
or other toxic bone marrow damage. Chemotherapy may
produce a remission in AML but the disease is characterised
by relapse which is often resistant to further cytotoxic treat-
ment. CLL is a disease of slow progression with accumula-
tion of malignant lymphocytes in blood, bone marrow and
lymphoid tissue. Drug treatment can result in suppression of
lymphocyte count but with time re-emergence of the malig-
nant clone occurs and cure is not usually possible.
To identify the incidence and possible association of GST
pi and mdr-1 expression in leukaemia patients and to study
any treatment related changes in the expression of these
genes, we have investigated their expression in haemopoietic
cells of normal control subjects and untreated and treated
patients with MDS, AML and CLL.
Materials and methods
Methods for mdr-1 expression have previously been pub-
lished (Holmes et al., 1989, 1990a). GST pi expression was
investigated in total peripheral leucocytes of ten normal con-
trol subjects (4 men and 6 women) aged 23 to 83 years, and
total bone marrow of one normal male aged 75 years. None
of the normal control subjects had any significant exposure
to drugs or environmental toxins. Nine patients with MDS of
varying sub-type, 18 with AML of varying type and stage of
disease and 32 patients with CLL, both untreated and treated
of varying stage have also been investigated. For those
patients with MDS, none of whom had received cytotoxic
therapy, one bone marrow and eight peripheral blood sam-
ples were studied. For all cases of AML blood or bone
marrow contained greater than 90% blasts. Only peripheral
blood was studied in CLL and all samples contained greater
than 70% lymphocytes. All cases of AML were treated with
adriamycin, cytosine and thioguanine at presentation and if
refractory, or on relapse, with either bisantrene or mitoxant-
rone and cytosine. CLL patients were all treated with inter-
mittent or continuous low dose chlorambucil.
DNA and total RNA were extracted by lysis in guanidine
thiocyanate and centrifugation in a caesium chloride gradient
(Maniatis et al., 1982). Concentrations of mRNA were deter-
mined spectrophotometrically and duplicate slot blots were
made with five doubling dilutions of total mRNA (10 gg to
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0.625 tg) on to Hybond N (Amersham) membranes. Each
slot blot included the CEM line and its drug-resistant
derivative CEM/VLB/100 as negative and positive controls
respectively for mdr expression (Beck et al., 1979). Hy-
bridisation was carried out using a 414 bp fragment of the
mdr cDNA P5L-18 (Scotto et al., 1986) as described by
Holmes et al. (1989) and then to a full length GST pi cDNA
(Kano et al., 1987). Probes were labelled with 32PdCTP by
primer extension (Boehringer). Quantitation of RNA was
carried out by hybridisation with a human B-actin (PHA4.1)
probe (Khalili et al., 1983). The blots were finally washed
with 2 x SSC, (sodium chloride, sodium citrate), 1% SDS
(sodium dodecyl sulphate), at 65°C for 1 hour, and
0.1 x SSC 1% SDS at 60°C for 30 minutes for GST pi and B
actin respectively. Kodak XAR-5 film exposed at -70°C for
1-5 days was used for autoradiography. Relative levels of
GST pi expression were determined by densitometry.
Results
Results are summarised in Table I. The data relating to
mdr-1 expression in the same samples examined here have
been published previously (Holmes et al., 1989, 1990a).
Representative data for relative levels of GST pi expression
in a normal control, CEM and CEM/VLB/100 cell line and
patients with increased expression in MDS, AML and CLL
are shown in Figure 1. Total peripheral leucocytes from the
same 10 normal controls and total bone marrow from one
individual demonstrated a range of GST pi mRNA expres-
sion of 1 to 3 arbitrary units. It was hoped that analysis of
GST pi expression in normal myeloid and lymphoid fractions
in peripheral blood could be obtained as had been completed
with mdr analysis. However, no signal could be detected
from the relevant membranes and no RNA was available to
construct further blots. All peripheral blood samples con-
tained 30-40% lymphocytes whilst the one bone marrow
examined held less than 5% lymphocytes. It is not feasible to
obtain data on GST pi expression on normal blast cells since
approximately 108 cells are required for RNA extraction.
Therefore, no truly adequate control exists for the analysis of
GST pi expression in AML. We have compared GST pi
RNA level in CLL to those in total peripheral blood. Ideally
data on normal lymphoid fractions would have provided
better controls.
All pre-leukaemic and leukaemic samples contained GST
pi mRNA within a 28-fold range of variations in expression.
Eight of nine (one bone marrow, seven total peripheral
blood) patients with MDS of all sub-types demonstrated
Table I GST pi expression in normal control subjects, cell lines and
leukaemic samples
Relative levels ofRNA GSTpi
Results Mean + /-
Normal controls Number Standard Error Range
Total peripheral leucocytes 10 2.3 ± 0.2 1-3
Total bone marrow 1 2
Cell lines
CEM (parental drug sensitive
lymphoblastic line) 9
CEM/VLB/100 (drug resistant
mutant line) 9
Patients with increased GST pi expression
Mean + / -
Number Standard Error Range
MDS 8/9 5.6 ± 0.8 4-10
AML Untreated 4/5 7 ± 0.6 6-8
Secondary 1/5 6 6
Relapse or
Refractory 7/11 10.1 ± 2.9 4-24
CLL Untreated 3/7 13.7 ± 6.8 5-27
Treated 21/25 10.7± 1.58 4-28
GST pi mRNA (4-10 units) above the normal range.
Elevated RNA levels were seen in 12 of 18 cases of AML (5
peripheral blood, 7 bone marrow) including 4 of 5 untreated
AML (6-8 units), one of 5 secondary AML (secondary to
previous chemotherapy and radiotherapy for carcinoma of
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Figure 1 A = GST pi; B = B actin. Numbers 1-5 represent
doubling dilutions of RNA (10jg to 0.625ILg). Representative
RNA slot blots of parental sensitive (CEM) and drug resistant
(CEM/VLB/100) cell lines, normal leucocytes and patients with
MDS, AML and CLL showing increased GST pi expression. One
arbitrary unit represents the level of expression demonstrated in
normal leucocytes. Relative levels of GST expression were deter-
mined by densitometry. Slot 1, lane A does not give a represen-
tative signal of GST pi expression due to either RNA overloading
or the presence of an excess of RNA sample buffer. This signal is
not used in any subsequent densitometric analysis. Levels of GST
pi expressions are determined from the remaining 4 slots.GST PI EXPRESSION IN LEUKAEMIA 211
the breast, 6 units), and 7 of 11 cases of relapsed or refrac-
tory AML (4-24 units). Repeated measurements on three
patients with GST pi levels (6, 8, 13 units) at presentation
had the same or decreased expression after chemotherapy (2,
3, 6 units). Of the CLL patients 3 of 7 untreated (5-27 units)
and 21 of 25 treated (4-28 units) demonstrated increased
mRNA in peripheral blood. Sequential measurements on two
patients could not demonstrate a change in gene expression
with exposure to intermittent chlorambucil.
Gene amplification of GST pi could not be demonstrated
in any of the patient material screened. Of all patients, those
with normal GST pi and mdr-I expression include none with
MDS, one case of relapsed secondary AML, two untreated
and four treated patients with CLL. Out of a total of 59
patients, only 7 patients had neither gene upregulated. In
view of the possible association between GST pi and mdr-l
expression, a comparison was made between the relative
levels in the same samples. There was no obvious association
except for a possible weak correlation between GST pi and
mdr-l mRNA levels in CLL (Figure 2).
Discussion
As it is likely that malignant cells can use several mechanisms
to achieve a drug-resistant state and maintain a proliferative
advantage we have investigated the possible associations and
relevance of two mechanisms that are currently considered to
be important. Moscow et al. (1989) reported over expression
of PGP and GST pi in the AdrR MCF-7 breast carcinoma
line and rat hyperplastic nodules. They further investigated
23 cases of lymphoma and observed generally higher levels of
mdr-l mRNA in low grade compared to high grade tumours
whilst GST pi levels were uniformly low. Analysis of 7 cases
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Figure 2 GST pi vs mdr RNA expression. Using Spearman's
Rank Order Correlation test gives non significant negative cor-
relation in MDS (r = 0.412) and AML (r = 0.314). Positive
association of GST pi and mdr mRNA expression in CLL group
(r = 0.335, p = 0.05, two tailed test).
of pre-B ALL suggested that increased GST pi expression is
present before chemotherapy and may be higher at relapse.
To date, there have been no studies comparing GST pi and
mdr-l expression in human pre-leukaemia, AML and CLL.
McQuaid et al. (1989) have investigated GST pi expression
alone in 2 cases of MDS, 9 of AML and 1 case of ALL and
found modest increases in expression in all cases when com-
pared to four normal controls. Their data further suggested
that, in two cases of AML and two of lymphoma, that
transcription levels of GST pi fell after the introduction of
chemotherapy indicating that perhaps gene upregulation is
not an important mechanism in the detoxification ofcytotox-
ics.
We have observed lower levels of GST pi mRNA in nor-
mal total peripheral leucocytes and total bone marrow. Data
on GST pi expression in normal lymphoid and myeloid
fractions are not available for technical reasons, as men-
tioned previously. In contrast, mdr-l mRNA levels whilst
low in normal lymphocyte populations can be high in normal
total peripheral leucocytes and bone marrow suggesting that
myeloid cells and possibly monocytes express high levels of
mdr-l mRNA. (Holmes et al., 1990a).
We have previously demonstrated mdr-l gene
amplification and increased RNA expression in the drug-
resistant CEM/VLB/100 leukaemic line when compared to
the parental sensitive CEM line (Holmes et al., 1989). How-
ever, both the sensitive and resistant lines express similar
levels of GST pi mRNA compared to normal peripheral
blood and bone marrow. This suggests, in agreement with
Moscow et al. (1989), that GST pi upregulation may be an
inherent feature of lymphoblastic leukaemia. However, ALL,
particularly in children, is chemosensitive raising a question
concerning the relevance of increased GST pi expression.
These data also suggest that the mdr-l and GST pi gene may
act independently to confer drug resistance.
Elevated levels of mdr-l mRNA as compared to the basal
expression of the drug sensitive CEM leukaemic cell line are
more common in secondary and relapsed/refractory AML
than in untreated AML (Holmes et al., 1989). Repeated
measurements in three patients with AML with basal levels
of mdr-l mRNA at presentation, that is comparable to the
CEM line, have shown that levels can be significantly in-
creased at relapse. In contrast, GST pi levels are more com-
monly elevated above the normal range for blood and bone
marrow in primary than secondary AML and repeated
measurements on the same three patients suggest that RNA
levels remain the same or fall after chemotherapy. This sug-
gests that, unlike mdr-l, GST pi is not inducible by the
therapeutic agents used. Furthermore, although GST pi may
be upregulated initially, other drug resistance mechanisms
may be relevant in subsequent clinical drug resistance.
For those patients with the pre-leukaemic syndrome,
MDS, elevations of GST pi above the normal range for
peripheral blood and bone marrow and mdr-1 mRNA
relative to the drug sensitive CEM line are commonly
observed. All patients demonstrated over expression of either
GST pi, or mdr-l.
We have previously demonstrated increased levels ofmdr-1
mRNA in approximately 50% of both untreated and treated
cases of CLL, with upregulation of the mdr-1 gene occurring
in response to intermittent chemotherapy with alkylating
agents (Holmes et al., 1990a). GST pi upregulation appears
more common in treated than untreated CLL although no
clear relationship could be demonstrated in two patients
treated with chlorambucil. There are now various reports
which suggest an association between GST pi and mdr-l
expression (Kitahara et at., 1984; Gowan et at., 1986; Burt et
al., 1988).
In AML and CLL patients all patterns of GST pi and
mdr-I expression were observed suggesting that these
mechanisms act independently. Only in CLL does there
appear to be a possible association between GST pi and mdr
expression (rs = 0.335, p = 0.05). No relationship could be
found with either GST pi or mdr-l expression and age, sex of
patient, FAB type of AML and MDS or stage of CLL.
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Within the AML and CLL groups there were patients, albeit
a minority, (7 out of 50) with clinically resistant disease and
no apparent involvement of either of these drug resistance
mechanisms, which suggests that other processes may be
clinically relevant.
Potmesil et al. (1988) have demonstrated low levels of
topoisomerase II in CLL suggesting this as a clinically
relevant route to a drug-resistant state for those tumours
with a large population of non-proliferating cells.
Although the clinical relevance of these data is not clear,
the relationship of mdr-I and GST pi expression to
chemotherapy may provide important considerations for the
future design of therapeutic regimes and suggest a complex
relationship between drug resistance mechanisms in
leukaemia.
We would like to thank Drs. Whittaker and Bentley for allowing us
to investigate their patients. This work was supported by the
Leukaemia Research Fund, Imperial Cancer Research Fund and the
Welsh Scheme for Health and Social Research.
References
BECK, W.T., MUELLER, T.J., & TANZER, L.R. (1979). Altered surface
membrane glycoproteins in vinca alkaloid resistance human
leukaemic lymphoblasts. Cancer Res., 39, 2070.
BIEDLER, J.L. & RIEHM, H. (1970). Cellular resistance to actino-
mycin D in Chinese hamster cells in vitro: cross-resistance,
radioautographic and cytogenetic studies. Cancer Res., 30, 1174.
BURT, R., GARFIELD, S., JOHNSON, K. & THORGEIRSSON, S. (1988).
Transformation of rat liver epithelial cells with v-H RAS or v
RAF causes expression of mdr-1 glutathione S transferase - P
and increased resistance to cytotoxic chemicals. Carcinogenesis, 9,
2329.
CHEN, C.J., CHIN, J.E., UEDA, K. & 4 others (1986). Internal duplica-
tion and homology with bacterial transport proteins in the mdr-1
(P glycoprotein) gene from multidrug resistant human cells. Cell,
47, 381.
COWAN, K., BATIST, G., TUPPULE, A., SINHA, B. & MYERS, C.
(1986). Similar biochemical changes associated with multidrug
resistance in human breast cancer cells and carcinogen induced
resistance to xenobiotics in rats. Proc. Natl. Acad Sci. USA, 83,
9328.
GOLDSTEIN, L., GALSKI, H., FOJO, A. & 11 others (1989). Expression
of a multidrug resistance gene in human cancers. J Natl Cancer
Inst., 81, 116.
HAYES, J.D. & WOLF, C.R. (1988). Glutathione transferases in drug
resistance in glutathione conjugation: mechanisms and biological
significance, Sies H. and Ketterer B. (eds) Academic press: New
York, 315.
HOLMES, J.A., JACOBS, A., CARTER, G., JANOWSKA-WIECZOREK,
A. & PADUA, R.A. (1989). Multidrug resistance in haemopoietic
cell lines myelodysplastic syndromes and acute myeloblastic
leukaemia. Brit. J. Haematol., 72, 40.
HOLMES, J.A., JACOBS, A., CARTER, G., WHITTAKER, J.A., BENT-
LEY, D.P. & PADUA, R.A. (1990a). Is the mdr-I gene relevant in
chronic lymphocytic leukaemia? Leukaemia, 4, 216.
HOLMES, J.A. (1990b). Multidrug resistance in leukaemia. Leukaemia
and Lymphoma, (in press).
JULIANO, R.L. & LING, V. (1976). A surface glycoprotein modulating
drug permeability in Chinese hamster ovary cell mutants.
Biochimica et Biophysica Acta, 455, 152.
KANO, T., SAKAI, M. & MURAMATSU, M. (1987). Structure and
expression of a human class pi glutathione-s-transferase
messenger RNA. Cancer Res., 47, 5626.
KARTNER, N., EVERNDEN-PORELLE, D., BRADLEY, G. & LING, V.
(1985). Detection of P-glycoprotein in multidrug-resistant cell
lines by monoclonal antibodies. Nature, 316, 820.
KETTERER, B., MEYER, D.J., COLES, B., TAYLOR, J.B. & PEMBLE,
S.E (1986). In: Antimutagenesis and Anticarcogenesis Mechanisms.
SHANKEL, D.M., HARTMAN, P.E., KADA, T. & HOLLAENDER, A. (eds).
New York: Plenum Press, 103.
KHALILI, K., SALAS, C. & WEINMANN, R. (1983). Isolation and
characterisation of human actin genes cloned in phage lamda
vectors. Gene, 21, 9.
KITAHARA, A. SATOH, K., NISHIMURA, K. & 5 others (1984).
Changes in molecular forms of rat hepatic glutathione S-
transferase during chemical hepatocarcinogenesis. Cancer
Research, 44, 2698.
MANIATIS, T., FRITSCH, E.F. & SAMBROOK, J. (1982). Molecular
Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory:
New York.
MANNERVIK, B., ALIN, P., GUTHENBERG, C. & 4 others (1985).
Identification of three classes of cytosolic glutathione transferases
common to several mammalian species: Correlation between
structural data and enzymatic properties. Proc. Natl. Acad. Sci.
USA., 82, 7202.
MOSCOW, J.A., FAIRCHILD, C.R., MADDEN, M.J. & 7 others (1989).
Expression of anionic glutathione-S-transferase and P-
glycoprotein genes in human tissues and tumors. Cancer Res., 49,
1422.
MCQUAID, S., MCCANN, S., DAY, P., LAWLOR, E. & HUMPHRIES, P.
(1989). Observations on the transcriptional activity of the
glutathione S transferase gene in human haematological malig-
nancies and in the peripheral leucocytes of cancer patients under
chemotherapy. Br. J. Cancer, 59, 540.
POTMESIL, M., HSIANG, Y., LIU, L. & 9 others (1988). Resistance of
human leukaemic and normal lymphocytes to drug induced DNA
cleavage and low levels of DNA topoisomerase II. Cancer Res.,
48, 3537.
SCOTTO, K.W., BIEDLER, J.L. & MELERA, P.W. (1986). Amplification
and expression of genes associated with multidrug resistance in
mammalian cells. Science, 232, 751.